The 'last word' Finally, as a test of the relevance of policy-making to statistics, the chairman asked each of the main speakers what they would advocate concerning the. place of delivery towards the year 2000, if they were in a position to create policy. Alison Macfarlane said that firstly she would want the implications of the statistics currently available clearly explained to parents and professionals, and then in the light of the results of the home birth survey -and given that risk assessment was only available in relation to factors that had previously been measured -she would make facilities for home birth available to those who wanted them, backed up by the best available screening process.
Rona Campbell felt that women should be allowed a greater choice and that their wishes should dictate the facilities that were provided, as the outcome of their choices was carefully monitored. Marjorie Tew wanted to see all obstacles to home birth, such as the fear of GP reprisals, removed, and mothers advised that hospital delivery was safer for them only where there was good evidence that this was so. She would also halt the closure of isolated GP units and where possible reopen those that had closed. There would be no funding for technological equipment, except for pilot studies, until it was demonstrated to be of value. Lastly, she would ensure that more emphasis was placed on acquiring low-technology midwifery skills, rather than the skills of hightechnology obstetrics, in the training of midwives and general practitioners. Dr Alan McGregor (University of Wales, College of Medicine, Cardiff) presented his studies on the antibodies to human thyroid microsome, some of which had been carried out in collaboration with Drs Mirakian and Banga (Middlesex Hospital, London) . Following the studies of Khoury et al. (1984) , the human microsomal antigen is currently viewed as the vesicular membrane of the exocytotic vesicle which transports thyroglobulin from inside the cell to the surface membrane. This antigen is therefore expressed at the surface. Microsomal antigen was prepared relatively free of thyroglobulin and ELISA developed to detect the presence of microsomal autoantibodies. This ELISA correlated well but was more sensitive than the conventional haemagglutination or immunofluorescence assays (Weetman et al. 1984) . The intra-assay variation was extremely good but the inter-assay variability rendered it advisable to run all samples in one trial in the one assay. This assay made it possible to follow in vivo and in vitro the response to therapies such as radioiodine, carbimazole or methimazole.
In their screen of 100 patients with Graves' disease, 90 had antibody to thyroid microsome and 35 to thyroglobulin.
Monoclonal antibodies have been raised by Dr McGregor and his colleagues to thyroid microsomes. One of these antibodies was shown to be an IgM antibody which recognized the intracellular microsomal fraction, whereas another stained the villous membrane. This latter antibody was shown to bind to the thyroid monolayers and be capable of killing thyroid cells. Furthermore, antibody to thyroid microsome was able to inhibit cAMP release by thyroid cells stimulated with thyroid-simulating hormone (TSH). Antibodies to thyroglobulin did not have this effect.
Professor Donald Munro (Sheffield) presented an interesting history of studies on Graves' disease (Adams & Purves 1956) . His overview covered the elucidation of the role of the long-acting thyroid stimulator (LATS) and an antibody which blocked LATS activity (LATS-P). It was proposed that isolation of the relevant monoclonal antibodies and purification of the TSH receptor would further our understanding of this disease, much as had already been accomplished with the acetylcholine receptor and myasthenia gravis (Munro 1984) .
The availability of the autoantigen and the possibility of antigen presentation by thyroid epithelial cells (thyrocytes) was discussed by Drs Franco Bottazzo (Middlesex Hospital, London) al. 1984) it has been possible to demonstrate that thyroid epithelial cells bearing class II antigens can present but not process antigen. T-cell clones isolated from patients with Graves' disease fell into three categories. The biggest group seemed unresponsive to autologous thyrocytes and autologous blood but did respond to interleukin-2 (IL-2). Another group appeared to respond to self MHC, responding to thyroid cells and autologous peripheral blood. The third and perhaps most interesting group recognized autologous thyroid specifically. This third group of cells were of the helper/inducer phenotype (OKT4+) and, when cultured with class II bearing thyroid cells, expressed IL-2 receptors. Stimulation of these T-cell clones is blocked by antibodies specific for class II MHC antigens, and it is therefore likely that these T-cell clones were being stimulated by membrane-bound self antigen being presented by the thyrocyte in association with class II molecules (Londei et al. 1985) .
In Autoimmune pathology affecting the neuromuscular junction was the next topic discussed. Dr A Vincent (Royal Free Hospital, London) described the Lambert-Eaton syndrome, a disease in which an autoimmune association has been noted, and which was frequently associated with smallcell carcinoma of the lung. In these patients (71% of which were HLA-B8) plasma exchange and immunosuppression had a significant effect. If IgG from a patient was passively transferred into mice, a diminished quantal content of acetylcholine release was observed, similar to that found in muscle biopsies from patients with Lambert-Eaton syndrome. Collaborative work with Dr A Engle (Mayo Clinic, USA) had shown a reduction in active zone particles on the presynaptic nerve terminal in these mice, and A Roberts, B Lang and others at the Rnoyal Free Hospital had shown a reduction in calcium flux into a carcinoma cell line grown in the presence of Lambert-Eaton IgG; these findings suggested that autoantibodies were directed at the calcium channels on the presynaptic membrane.
Myasthenia gravis has clearly been shown to have an autoimmune basis with the autoantibody recognizing the acetylcholine receptor (Lindstrom 1977) . There appeared to be some linkage, particularly in young patients without thymoma, to HLA-B8, but unlike Lambert-Eaton syndrome there was no association in Europeans with particular Gm allotype markers. Monoclonal antibodies against the human acetylcholine receptor can distinguish between normal and denervated muscle receptor. These monoclonal antibodies can be divided into five groups according to their antigenic specificities, and provided a useful method of analysing the binding sites for the human autoantibodies which were very heterogeneous. Rabbit anti-idiotype prepared against the human autoantibody has shown little crossreactivity between the idiotypes of different patients. In patients followed over a six-year period, autoantibodies showed marked fluctuations but there was no alteration in the idiotypic profile.
In the final presentation, Dr E Gale (St Bartholomew's Hospital, London) discussed some clinical implications of autoimmunity in Type 1 diabetes mellitus. There was a 30-50% concordance rate in identical twins for insulindependent diabetes; the fact that this concordance rate was no higher showed that this form of diabetes was not simply a genetically determined disease. Isolated case reports and the demonstration of a peak incidence of childhood diabetes in the spring and autumn had led to speculation concerning a viral aetiology, but it seemed more likely that viruses were a precipitating rather than initiating factor. This was borne out by the demonstration of a prolonged latency period characterized by the presence of circulating islet cell antibodies. These antibodies were present in 60-80% of newly diagnosed patients, but declined with time thereafter. However, in prospective family studies, such as the ongoing Bart's/Windsor/Middlesex family studywhich had recently been merged with the Oxford family study to provide a total of 280 families -it had been possible to demonstrate the appearance of these antibodies up to 7 years before clinical diagnosis. Complement-fixing islet cell antibodies (CF-ICA) had, in particular, proved a useful index of risk, and about 30% of first-degree relatives possessing this antibody had developed diabetes in the course of follow up. Dr Gale said that an extended family study was to begin shortly, and it was hoped that this would help to define the genetic, immunological and environmental factors involved in the pathogenesis of this condition.
The elegant studies of Dr B Dean (St Bartholomew's) and Dr Franco Bottazzo (Middlesex) have shown aberrant expression of HLA-DR on the beta-cells in the pancreas of a diabetic child and the presence of T-cells of the T-suppressor/cytotoxic phenotype (Bottazzo et al. 1985) . Fewer cells of the T-helper phenotype were found. Class I and II MHC antigens showed increased expression on the large capillary endothelium cells around the islets. Glucagon and somatostatin-containing cells had no surface HLA-DR antigens. These findings could be interpreted as supporting the proposal of Bottazzo et al. (1983) that HLA-DR expression on the endocrine cells allows membrane-bound self antigen to be presented to the immune system and autoimmune disease to be initiated.
